Key result
Lipid-lowering therapy resulted in higher LDL-C target achievement rates compared to no treatment in Vietnamese patients with stable CAD and ACS.
Why the study?
Patients with stable coronary artery disease or acute coronary syndrome have a high risk of recurrent cardiovascular events, but country-specific data on dyslipidemia extent and treatment were lacking.
Does lipid-lowering therapy improve LDL-C target achievement in patients with stable coronary artery disease or acute coronary syndrome?
Observational (n=612)
Yes
Does lipid-lowering therapy improve LDL-C target achievement in patients with stable coronary artery disease or acute coronary syndrome?
In Vietnamese patients with CAD or ACS, lipid-lowering therapy use is high but LDL-C target achievement remains low, highlighting a gap in optimal lipid management.
Answers are grounded in this paper and cite their sources.
Supports lipid-lowering therapy in coronary syndromes; reinforces low-certainty evidence of CVD benefit.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Viet et al. (2018) conducted an observational in Stable coronary artery disease and acute coronary syndrome (n=612). Lipid-lowering therapy vs. No lipid-lowering therapy was evaluated on LDL-C target achievement rate (Stable CAD cohort) (p=0.11). Lipid-lowering therapy resulted in higher LDL-C target achievement rates compared to no treatment in Vietnamese patients with stable CAD and ACS.
Synapse has enriched 10 related papers. Consider them for comparative context: